Groundbreaking Gene-Editing Treatment Cures Baby: A Revolutionary Leap in Personalized Medicine

Something was clearly wrong with Kyle and Nicole Muldoon’s newborn, KJ. At just a week old, doctors feared he had a serious condition. They faced the heart-wrenching possibility of meningitis or sepsis. Finally, they got a definitive answer: KJ had a rare genetic disorder called CPS1 deficiency. This affects about one in 1.3 million babies. If he survived, he would likely face severe developmental challenges and eventually need a liver transplant. Unfortunately, half of babies with this disorder don’t make it past their first week.

At Children’s Hospital of Philadelphia, doctors offered comfort care, allowing the Muldoons to forgo aggressive treatments with such a grim outlook. “We loved him, and we didn’t want him to be suffering,” Ms. Muldoon shared. Yet, in a moment of hope, KJ’s parents chose to give him a chance.

KJ has since defied expectations. Now 9½ months old, he has made medical history as the first patient of any age to receive a custom gene-editing treatment designed just for him. Doctors created a specialized infusion to correct his specific genetic defect.

This groundbreaking work is being showcased at the annual meeting of the American Society of Gene & Cell Therapy and will also be published in the New England Journal of Medicine.

Gene therapy is evolving rapidly. In 2021, the FDA approved the first gene therapy for a genetic disorder that causes blindness, showing how far this field has come. According to a recent survey, nearly 80% of parents would consider gene editing for their children if it could prevent serious diseases. As discussions around ethical considerations continue, the hope for effective treatments grows.

KJ’s story highlights not just medical advances, but the resilience of families facing unimaginable challenges. It emphasizes the importance of innovation in modern medicine and fosters hope for countless families dealing with rare genetic disorders.



Source link

Rare and Orphan Diseases,Genetic Engineering,Babies and Infants,Crispr (DNA),DNA (Deoxyribonucleic Acid),Research,Federal Aid (US),Children’s Hospital of Philadelphia,New England Journal of Medicine,Danaher Corporation,Musunuru, Kiran,University of Pennsylvania,Urnov, Fyodor (1968- ),University of California, Berkeley,Ahrens-Nicklas, Rebecca